Celecoxib and Afatinib synergistic enhance radiotherapy sensitivity on human non-small cell lung cancer A549 cells

References

• Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. 1999. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5(10):2884–2890.
   PubMed Web of Science ®Google Scholar
• Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. 2002. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 277(31):27613–27621.
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Park C, Wright EG. 2005. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer. 5(11):867–875.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U, Rodemann HP. 2007. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 83(3):238–248.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cheki M, Yahyapour R, Farhood B, Rezaeyan A, Shabeeb D, Amini P, Rezapoor S, Najafi M. 2018. COX-2 in radiotherapy: a potential target for radioprotection and radiosensitization. Curr Mol Pharmacol. 11(3):173–183.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang Q, Shi D, Yao D, Zhang L, Xiong J, Xu B. 2016. Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling. J Toxicol Pathol. 29(4):253–259.
   PubMed Web of Science ®Google Scholar
• Chen YM, Perng RP, Tsai CM. 2005. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. J Chemother. 17(6):679–684.
   PubMed Web of Science ®Google Scholar
• Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. 2005. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther. 4(9):1448–1455.
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, et al. 2014. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. 2005. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 23(2):254–266.
   PubMed Web of Science ®Google Scholar
• Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP. 2008. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys. 70(1):203–212.
   PubMed Web of Science ®Google Scholar
• Gately S, Kerbel R. 2003. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res. 37:179–192.
   PubMed Web of Science ®Google Scholar
• Girard N. 2018. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 14(11):1117–1132.
   PubMed Web of Science ®Google Scholar
• Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. 2000. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 275(15):11397–11403.
   PubMed Web of Science ®Google Scholar
• Huang J, Yuan X, Pang Q, Zhang H, Yu J, Yang B, Zhou L, Zhang F, Liu F. 2018. Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells. Drug Des Devel Ther. 12:2223–2231.
   PubMed Web of Science ®Google Scholar
• Jachak SM. 2007. PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr Opin Investig Drugs. 8(5):411–415.
   PubMedGoogle Scholar
• Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC. 2007. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys. 67(3):888–896.
   PubMed Web of Science ®Google Scholar
• Kim W, Youn H, Kang C, Youn B. 2015. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis. 20(9):1242–1252.
   PubMed Web of Science ®Google Scholar
• Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. 2012. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat. 15(3):173–182.
   PubMed Web of Science ®Google Scholar
• Koki AT, Masferrer JL. 2002. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 9(2):28–35.
   PubMedGoogle Scholar
• Kumar S, Singh RK, Meena R. 2016. Emerging targets for radioprotection and radiosensitization in radiotherapy. Tumour Biol. 37(9):11589–11609.
   PubMedGoogle Scholar
• Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, et al. 2005. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 11(9):3342–3348.
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Samuels M, Wang X, Kong FM, Janne PA, Masters G, Katragadda S, Hodgson L, Bogart J, Bradley J, et al. 2015. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol. 10(1):143–147.
   PubMed Web of Science ®Google Scholar
• Liu B, Shi ZL, Feng J, Tao HM. 2008. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int. 32(5):494–501.
   PubMed Web of Science ®Google Scholar
• Liu R, Xu KP, Tan GS. 2015. Cyclooxygenase-2 inhibitors in lung cancer treatment: bench to bed. Eur J Pharmacol. 769:127–133.
   PubMed Web of Science ®Google Scholar
• McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. 2018. Radiation, inflammation and the immune response in cancer. Mamm Genome. 29(11–12):843–865.
   PubMed Web of Science ®Google Scholar
• Meng Z, Gan YH. 2015. Activating PTEN by COX-2 inhibitors antagonizes radiation-induced AKT activation contributing to radiosensitization. Biochem Biophys Res Commun. 460(2):198–204.
   PubMed Web of Science ®Google Scholar
• Milas L. 2003. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Am J Clin Oncol. 26(4):S66–S69.
   PubMed Web of Science ®Google Scholar
• Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. 2003. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology. 17(5):15–24.
   PubMedGoogle Scholar
• Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, et al. 2005. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 65(2):664–670.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Radons J. 2012. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2:58.
   PubMedGoogle Scholar
• Nakanishi M, Rosenberg DW. 2013. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 35(2):123–137.
   PubMed Web of Science ®Google Scholar
• Naruse T, Nishida Y, Hosono K, Ishiguro N. 2006. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 27(3):584–592.
   PubMed Web of Science ®Google Scholar
• Nijkamp MM, Span PN, Bussink J, Kaanders JH. 2013. Interaction of EGFR with the tumour microenvironment: implications for radiation treatment. Radiother Oncol. 108(1):17–23.
   PubMed Web of Science ®Google Scholar
• Pal I, Dey KK, Chaurasia M, Parida S, Das S, Rajesh Y, Sharma K, Chowdhury T, Mandal M. 2016. Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. Tumour Biol. 37(5):6389–6402.
   PubMedGoogle Scholar
• Park SW, Kim HS, Hah JW, Jeong WJ, Kim KH, Sung MW. 2010. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anticancer Drugs. 21(9):823–830.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. 2006. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 12(11):3381–3388.
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. 2010. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 49(11):1603–1616.
   PubMed Web of Science ®Google Scholar
• Salehifar E, Hosseinimehr SJ. 2016. The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers. Drug Discov Today. 21(4):654–662.
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK, Contessa JN, Dent P, Mikkelsen RB, Valerie K, Reardon DB, Bowers G, Lin PS. 1999. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Invest. 7(6):321–330.
   PubMedGoogle Scholar
• Searle EJ, Illidge TM, Stratford IJ. 2014. Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. Clin Oncol. 26(5):266–276.
   Web of Science ®Google Scholar
• Sun J, Liu NB, Zhuang HQ, Zhao LJ, Yuan ZY, Wang P. 2017. Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell. Cancer Biomark. 19(1):45–50.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Gerelchuluun A, Hong Z, Sun L, Zenkoh J, Moritake T, Tsuboi K. 2013. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol. 15(9):1186–1199.
   PubMed Web of Science ®Google Scholar
• Takhar H, Singhal N, Mislang A, Kumar R, Kim L, Selva-Nayagam S, Pittman K, Karapetis C, Borg M, Olver IN, et al. 2018. Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. Asia Pac J Clin Oncol. 14(1):91–100.
   PubMed Web of Science ®Google Scholar
• Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. 2003. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 9(4):1566–1572.
   PubMed Web of Science ®Google Scholar
• Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, Kashida Y, Yamaguchi M, Chang GD, Chen CS. 2008. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res. 68(8):2820–2830.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Jr., Posner MR. 2005. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 23(28):6976–6981.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, et al. 2015. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 26(9):1883–1889.
   PubMed Web of Science ®Google Scholar
• Xu T, Wang NS, Fu LL, Ye CY, Yu SQ, Mei CL. 2012. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Mol Biol Rep. 39(7):7743–7753.
   PubMed Web of Science ®Google Scholar
• Yang C, Liu X, Cao Q, Liang Q, Qiu X. 2011. Prostaglandin E receptors as inflammatory therapeutic targets for atherosclerosis. Life Sci. 88(5–6):201–205.
   PubMed Web of Science ®Google Scholar
• Zhang P, He D, Song E, Jiang M, Song Y. 2019. Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression. PLoS One. 14(10):e0223760.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM. 2005. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 11(17):6261–6269.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al. 2015. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 26(9):1877–1883.
   PubMed Web of Science ®Google Scholar